Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sona Nanotech Inc C.SONA

Alternate Symbol(s):  SNANF

Sona Nanotech Inc. is a nanotechnology life sciences company, which is engaged in developing targeted hyperthermia therapy. The Company has developed multiple methods for the manufacturing of various types of gold nanoparticles (GNR). It is engaged in research and development of its technology for use in multiplex diagnostic testing platforms and advanced biomedical applications. Its gold nanotechnologies are adapted for use in applications, as a safe and delivery system for multiple medical treatments, for the approval of various regulatory boards, including Health Canada and the Food and Drug administration (FDA). Its gold nanorod particles are manufactured without the use of cetyltrimethylammonium bromide (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company is focused on the development of a pre-clinical nanomedical therapy for the treatment of cancer using its biocompatible GNR.


CSE:SONA - Post by User

Comment by bluebeard123on Jun 29, 2021 8:28pm
176 Views
Post# 33470914

RE:Financials are out

RE:Financials are outThere is no revenue reported for the period Feb 1 - Apr 30, 2021. From this we can conclude that there were no Covid 19 LFA  V1 sales. The market did not react to this because the failed V1 commercialization and failed V2 clinical tests are already baked into the current share price. The good news is that they have $2M in cash raised from PP in December, warrants, ATM financing and government grant. There is no immediate solvency risk. The MD&A doesn't give any new information. It's all been covered in the monthly CSE Form 7 filings. Overall, no surprises and no new information. I expect share price to remain within the current trading range in the 0.30s. IMO management will do a pivot. In their investment presentation (on their website), they said they will commercialize the bovine TB test and concussion test. They also talk about commercializing consumer health testing LFAs. I am personally looking to see whether they bring forward these activities forward much faster. This will determine whether I purchase more or whether I sell my initial position which I just purchassed. Again, I am looking forward to good discussion. I will pi$$ on anyone who pi$$es on me. I have already put on ignore MikeyH, Dart, Moemoney, Kaiser and a few others who pollute this board.with utter garbage commentary. MikeyH even offers ill will to you and he hopes you lose all your money. Kaiser is a total bore and can't get off asking how Dart's and Moemoney's $1000+ projection is going. Give it up.  Kaiser, Dart, MikeyH and Moemoney - go spead your wisdom somewhere else, like a QAon forum. They will like you there.. 
<< Previous
Bullboard Posts
Next >>